The Experts below are selected from a list of 177 Experts worldwide ranked by ideXlab platform
Jose R Trujillo - One of the best experts on this subject based on the ideXlab platform.
-
REVIEW Open Access New insights into HIV-1-primary skin disorders
2013Co-Authors: Filiberto Cedeno-laurent, Minerva Gómez-flores, Nora Mendez, Jesús Ancer-rodríguez, Joseph L Bryant, Anthony A Gaspari, Jose R TrujilloAbstract:Since the first reports of AIDS, skin involvement has become a burdensome stigma for seropositive patients and a challenging task for dermatologist and infectious disease specialists due to the severe and recalcitrant nature of the conditions. Dermatologic manifestations in AIDS patients act as markers of disease progression, a fact that enhances the importance of understanding their pathogenesis. Broadly, cutaneous disorders associated with HIV type-1 infection can be classified as primary and secondary. While the pathogenesis of secondary complications, such as opportunistic infections and skin tumours, is directly correlated with a decline in the CD4 + T cell count, the origin of the certain manifestations primarily associated with the retroviral infection itself still remains under investigation. The focus of this review is to highlight the immunological phenomena that occur in the skin of HIV-1-seropositive patients, which ultimately lead to skin disorders, such as seborrhoeic dermatitis, atopic dermatitis, psoriasis and Eosinophilic Folliculitis. Furthermore, we compile the latest data on how shifts in the cytokines milieu, impairments of the innate immune compartment, reactions to xenobiotics and autoimmunity are causative agents in HIV-1driven skin diseases. Additionally, we provide a thorough analysis of the small animal models currently used to study HIV-1-associated skin complications, centering on transgenic rodent models, which unfortunately, have no
-
New insights into HIV-1-primary skin disorders
Journal of the International AIDS Society, 2011Co-Authors: Filiberto Cedeno-laurent, Minerva Gómez-flores, Nora Mendez, Jesús Ancer-rodríguez, Joseph L Bryant, Anthony A Gaspari, Jose R TrujilloAbstract:Since the first reports of AIDS, skin involvement has become a burdensome stigma for seropositive patients and a challenging task for dermatologist and infectious disease specialists due to the severe and recalcitrant nature of the conditions. Dermatologic manifestations in AIDS patients act as markers of disease progression, a fact that enhances the importance of understanding their pathogenesis. Broadly, cutaneous disorders associated with HIV type-1 infection can be classified as primary and secondary. While the pathogenesis of secondary complications, such as opportunistic infections and skin tumours, is directly correlated with a decline in the CD4^+ T cell count, the origin of the certain manifestations primarily associated with the retroviral infection itself still remains under investigation. The focus of this review is to highlight the immunological phenomena that occur in the skin of HIV-1-seropositive patients, which ultimately lead to skin disorders, such as seborrhoeic dermatitis, atopic dermatitis, psoriasis and Eosinophilic Folliculitis. Furthermore, we compile the latest data on how shifts in the cytokines milieu, impairments of the innate immune compartment, reactions to xenobiotics and autoimmunity are causative agents in HIV-1-driven skin diseases. Additionally, we provide a thorough analysis of the small animal models currently used to study HIV-1-associated skin complications, centering on transgenic rodent models, which unfortunately, have not been able to fully unveil the role of HIV-1 genes in the pathogenesis of their primarily associated dermatological manifestations.
Hiroshi Shimizu - One of the best experts on this subject based on the ideXlab platform.
-
Eosinophilic Folliculitis in a patient after allogeneic bone marrow transplantation case report and review of the literature
American Journal of Hematology, 2004Co-Authors: Mitsuhito Ota, Tadamichi Shimizu, Satoshi Hashino, Hiroshi ShimizuAbstract:We describe a patient with Eosinophilic Folliculitis (EF) that developed 3 months after allogeneic bone marrow transplantation (BMT) for chronic myelogenous leukemia. Skin biopsy specimen revealed numerous eosinophil infiltrations from the hair follicles to the sebaceous glands. No sign of skin graft-versus-host disease (GVHD) was found. The skin lesions and peripheral eosinophilia subsided within 5 weeks. In the following 8 months, the rash did not recur and GVHD has not developed. Taken together with previous reports, the present case demonstrates that it is important to recognize this distinct skin condition to avoid an inference that it may manifest itself as one of the signs of skin GVHD.
Filiberto Cedeno-laurent - One of the best experts on this subject based on the ideXlab platform.
-
REVIEW Open Access New insights into HIV-1-primary skin disorders
2013Co-Authors: Filiberto Cedeno-laurent, Minerva Gómez-flores, Nora Mendez, Jesús Ancer-rodríguez, Joseph L Bryant, Anthony A Gaspari, Jose R TrujilloAbstract:Since the first reports of AIDS, skin involvement has become a burdensome stigma for seropositive patients and a challenging task for dermatologist and infectious disease specialists due to the severe and recalcitrant nature of the conditions. Dermatologic manifestations in AIDS patients act as markers of disease progression, a fact that enhances the importance of understanding their pathogenesis. Broadly, cutaneous disorders associated with HIV type-1 infection can be classified as primary and secondary. While the pathogenesis of secondary complications, such as opportunistic infections and skin tumours, is directly correlated with a decline in the CD4 + T cell count, the origin of the certain manifestations primarily associated with the retroviral infection itself still remains under investigation. The focus of this review is to highlight the immunological phenomena that occur in the skin of HIV-1-seropositive patients, which ultimately lead to skin disorders, such as seborrhoeic dermatitis, atopic dermatitis, psoriasis and Eosinophilic Folliculitis. Furthermore, we compile the latest data on how shifts in the cytokines milieu, impairments of the innate immune compartment, reactions to xenobiotics and autoimmunity are causative agents in HIV-1driven skin diseases. Additionally, we provide a thorough analysis of the small animal models currently used to study HIV-1-associated skin complications, centering on transgenic rodent models, which unfortunately, have no
-
New insights into HIV-1-primary skin disorders
Journal of the International AIDS Society, 2011Co-Authors: Filiberto Cedeno-laurent, Minerva Gómez-flores, Nora Mendez, Jesús Ancer-rodríguez, Joseph L Bryant, Anthony A Gaspari, Jose R TrujilloAbstract:Since the first reports of AIDS, skin involvement has become a burdensome stigma for seropositive patients and a challenging task for dermatologist and infectious disease specialists due to the severe and recalcitrant nature of the conditions. Dermatologic manifestations in AIDS patients act as markers of disease progression, a fact that enhances the importance of understanding their pathogenesis. Broadly, cutaneous disorders associated with HIV type-1 infection can be classified as primary and secondary. While the pathogenesis of secondary complications, such as opportunistic infections and skin tumours, is directly correlated with a decline in the CD4^+ T cell count, the origin of the certain manifestations primarily associated with the retroviral infection itself still remains under investigation. The focus of this review is to highlight the immunological phenomena that occur in the skin of HIV-1-seropositive patients, which ultimately lead to skin disorders, such as seborrhoeic dermatitis, atopic dermatitis, psoriasis and Eosinophilic Folliculitis. Furthermore, we compile the latest data on how shifts in the cytokines milieu, impairments of the innate immune compartment, reactions to xenobiotics and autoimmunity are causative agents in HIV-1-driven skin diseases. Additionally, we provide a thorough analysis of the small animal models currently used to study HIV-1-associated skin complications, centering on transgenic rodent models, which unfortunately, have not been able to fully unveil the role of HIV-1 genes in the pathogenesis of their primarily associated dermatological manifestations.
Hancco Jorge - One of the best experts on this subject based on the ideXlab platform.
-
Topical capsaicin 0,075% versus menthol 1% efficacy and safety in HIV-associated eosinofilic Folliculitis
Facultad de Medicina Humana de la Universidad Nacional Mayor de San Marcos, 2013Co-Authors: Galarza Carlos, Ramos Willy, Chía Humberto, Ronceros Gerardo, Santiani Jesús, Gutiérrez Ericson, Ñavincopa Marcos, Vilcarromero María, Ávila Jack, Hancco JorgeAbstract:Objetivo: Determinar la eficacia y seguridad de la terapia tópica con capsaicina 0,075% versus mentol 1% en el tratamiento del prurito de la foliculitis eosinofílica asociada al virus de la inmunodeficiencia adquirida (VIH). Diseño: Estudio clínico aleatorizado y doble ciego. Lugar: Servicios de Enfermedades Infecciosas y Tropicales (SEIT) y Dermatología, Hospital Nacional Dos de Mayo, Lima, Perú. Participantes: Pacientes con foliculitis eosinofílica asociada al VIH. Intervenciones: La muestra estuvo constituida por 40 pacientes con foliculitis eosinofílica asociada al VIH, quienes fueron distribuidos mediante muestreo aleatorio sistemático en dos grupos: el grupo 1 conformado por 20 pacientes que recibieron la terapia 1; y el grupo 2, conformado por 20 pacientes que recibieron la terapia 2. Los pacientes recibieron tratamiento con capsaicina al 0,075% y mentol 1%; la aplicación se realizó en el área afectada, cada 6 horas, durante 45 días. Se implementó un sistema de visitas (domiciliarias u hospitalarias), se evaluó la eficacia en la reducción del prurito (escala de Likert) y se registró los eventos. Principales medidas de resultados: Respuesta clínica a la administración de capsaicina y mentol. Resultados: La respuesta fue buena en 90% de los pacientes que recibieron capsaicina 0,075%, en comparación con 40% en el grupo que recibió mentol al 1% (p = 0,001), con OR = 0,074 (IC 95 %: 0,013 – 0,411). La eficacia de las terapias tópicas fue modificada por el recuento de linfocitos CD4 (p 0,05). Conclusiones: La terapia tópica con capsaicina es eficaz y segura en el tratamiento del prurito, en la foliculitis eosinofílica asociada al VIH.Objetive: To determine efficacy and safety of capsaicin 0,075% topical therapy in the treatment of pruritus due to Eosinophilic Folliculitis in HIV patients with lymphocyte count CD4 (+) 0,05). Conclusions: Capsaicin topical therapy is effective and safe in the treatment of pruritus in HIV-associated Eosinophilic Folliculitis
-
Topical capsaicin 0,075% versus menthol 1% efficacy and safety in HIV-associated eosinofilic Folliculitis
'Universidad Nacional Mayor de San Marcos Vicerectorado de Investigacion', 2007Co-Authors: Galarza Carlos, Ramos Willy, Chía Humberto, Ronceros Gerardo, Santiani Jesús, Gutiérrez Ericson, Ñavincopa Marcos, Vilcarromero María, Ávila Jack, Hancco JorgeAbstract:Objetivo: Determinar la eficacia y seguridad de la terapia tópica con capsaicina 0,075% versus mentol 1% en el tratamiento del prurito de la foliculitis eosinofílica asociada al virus de la inmunodeficiencia adquirida (VIH). Diseño: Estudio clínico aleatorizado y doble ciego. Lugar: Servicios de Enfermedades Infecciosas y Tropicales (SEIT) y Dermatología, Hospital Nacional Dos de Mayo, Lima, Perú. Participantes: Pacientes con foliculitis eosinofílica asociada al VIH. Intervenciones: La muestra estuvo constituida por 40 pacientes con foliculitis eosinofílica asociada al VIH, quienes fueron distribuidos mediante muestreo aleatorio sistemático en dos grupos: el grupo 1 conformado por 20 pacientes que recibieron la terapia 1; y el grupo 2, conformado por 20 pacientes que recibieron la terapia 2. Los pacientes recibieron tratamiento con capsaicina al 0,075% y mentol 1%; la aplicación se realizó en el área afectada, cada 6 horas, durante 45 días. Se implementó un sistema de visitas (domiciliarias u hospitalarias), se evaluó la eficacia en la reducción del prurito (escala de Likert) y se registró los eventos. Principales medidas de resultados: Respuesta clínica a la administración de capsaicina y mentol. Resultados: La respuesta fue buena en 90% de los pacientes que recibieron capsaicina 0,075%, en comparación con 40% en el grupo que recibió mentol al 1% (p = 0,001), con OR = 0,074 (IC 95 %: 0,013 – 0,411). La eficacia de las terapias tópicas fue modificada por el recuento de linfocitos CD4 (p<0,001). La presencia de enfermedades oportunistas (p = 0,252) no afectó la eficacia de las terapias. Se presentaron efectos adversos locales (eritema y ardor) en 3 pacientes (15%) que recibieron capsaicina 0,075%, mientras que en el grupo que recibió mentol al 1% un paciente (5%) presentó eritema, no hallándose diferencia estadísticamente significativa (p > 0,05). Conclusiones: La terapia tópica con capsaicina es eficaz y segura en el tratamiento del prurito, en la foliculitis eosinofílica asociada al VIH.Objetive: To determine efficacy and safety of capsaicin 0,075% topical therapy in the treatment of pruritus due to Eosinophilic Folliculitis in HIV patients with lymphocyte count CD4 (+) <250 x mm3. Design: Randomized clinical trial, double blind study. Setting: Infectious and Tropical Diseases Service and Dermatology Service, Hospital Nacional Dos de Mayo, Lima, Peru. Participants: Patients with VIH-associated Eosinophilic Folliculitis. Interventions: Forty patients with HIV-associated Eosinophilic Folliculitis were randomly distributed in two groups: group 1 included 20 patients that received sample 1 and group 2, 20 patients that received sample 2. Patients received capsaicin 0,075% and menthol 1% treatments (marked as sample 1 and sample 2). Instructions on topical use each 6 hours were given to patients. Visits were programmed to evaluate efficacy and monitor adverse events by study drugs. Main outcome measures: Capsaicin and menthol administration clinical outcome. Results: We found good response in 90% of patients receiving capsaicin 0,075% (18/20) versus 40% of the group treated with menthol 1% (88/20), with significant statistical difference (p= 0,001), OR = 0,074% (IC 95%: 0,013 – 0,411). Topical therapy efficacy was altered by CD4 lymphocyte count (p< 0,001); otherwise the occurrence of opportunistic diseases (p= 0,252) did not affect therapy efficacy. There were local adverse events (erithema and heat) in 3 patients (15%) who received capsaicin 0,075% and only in one patient (5%) of group 2 (menthol) who presented erithema (5%), with no significant statistical difference (p> 0,05). Conclusions: Capsaicin topical therapy is effective and safe in the treatment of pruritus in HIV-associated Eosinophilic Folliculitis
Richard A Johnson - One of the best experts on this subject based on the ideXlab platform.
-
isotretinoin treatment of human immunodeficiency virus associated Eosinophilic Folliculitis
2017Co-Authors: Clark C Otley, Marc R Avram, Richard A JohnsonAbstract:virus\x=req-\ associated Eosinophilic Folliculitis is a pruritic eruption seen in advanced infection with human immunodeficiency virus. The associated pruritus causes considerable morbidity and is poorly responsive to conventional therapy. We studied whether isotretinoin would prove efficacious in the treatment of human immunodeficiency virus-associated Eosinophilic Folliculitis. Seven patients with biopsy specimen-proved human immunodeficiency virus-associated Eosinophilic Folliculitis were treated with a mean of 7.7 weeks of isotretinoin therapy and their responses were monitored. Observations: All patients responded with complete symptomatologic and clinical remission within 1 to 4 weeks of isotretinoin therapy. Four (57%) of seven patients remained in complete remission after just one course of isotretinoin therapy, while three (43%) of seven patients experienced up to three brief relapses, all rapidly responsive to further isotretinoin therapy. Patients remained free of disease for up to 9 months after therapy. Conclusions: Isotretinoin appears to be a promising treatment for human immunodeficiency virus-associated Eosinophilic Folliculitis. A double-blind, placebo\x=req-\ controlled trial is indicated. (Arch Dermatol. 1995;131:1047-1050)
-
isotretinoin treatment of human immunodeficiency virus associated Eosinophilic Folliculitis results of an open pilot trial
Archives of Dermatology, 1995Co-Authors: Clark C Otley, Marc R Avram, Richard A JohnsonAbstract:Background: Human immunodeficiency virus-associated Eosinophilic Folliculitis is a pruritic eruption seen in advanced infection with human immunodeficiency virus. The associated pruritus causes considerable morbidity and is poorly responsive to conventional therapy. We studied whether isotretinoin would prove efficacious in the treatment of human immunodeficiency virus-associated Eosinophilic Folliculitis. Seven patients with biopsy specimen-proved human immunodeficiency virus-associated Eosinophilic Folliculitis were treated with a mean of 7.7 weeks of isotretinoin therapy and their responses were monitored. Observations: All patients responded with complete symptomatologic and clinical remission within 1 to 4 weeks of isotretinoin therapy. Four (57%) of seven patients remained in complete remission after just one course of isotretinoin therapy, while three (43%) of seven patients experienced up to three brief relapses, all rapidly responsive to further isotretinoin therapy. Patients remained free of disease for up to 9 months after therapy. Conclusions: Isotretinoin appears to be a promising treatment for human immunodeficiency virus-associated Eosinophilic Folliculitis. A double-blind, placebo-controlled trial is indicated. (Arch Dermatol. 1995;131:1047-1050)